Compare Alexandria Real Estate Equities Inc (ARE) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Enveric Biosciences Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $47.9 (market cap $8.34B), while Enveric Biosciences Inc trades at $1.34 (market cap $5.44M). The key difference: Alexandria Real Estate Equities Inc is far larger — about 1533.1× Enveric Biosciences Inc's market cap, and Alexandria Real Estate Equities Inc pays a 6.02% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ARE | ENVB | |
|---|---|---|
Market Cap | $8.34B | $5.44M |
Sector | Real Estate | Health |
52-Week High | $87.45 | $17.40 |
52-Week Low | $40.41 | $1.28 |
Enterprise Value | $20.80B | $529.67K |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $47.88, down 1.3% on the day, with a bearish technical signal and mixed fundamentals. The stock shows a high P/E of 102.99 and negative net income margin of -37.09%, though it maintains a strong gross margin of 67.76% and positive operating cash flow. Recent news highlights corporate responsibility initiatives and a declared dividend of $0.72 per share for Q2 2026.
The outlook is cautious due to profitability challenges and elevated debt, but analyst consensus suggests moderate upside to a $51.00 price target. Key risks include sustained negative earnings and interest rate sensitivity, while institutional sentiment leans neutral with 58.33% hold ratings.
ENVB trades at $1.35, down 5.59% today, with a bearish technical signal from moving averages. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
Outlook remains speculative with high financial risk due to negative ROE and ROA, but analyst consensus is 75% buy. Key risks include clinical trial outcomes and cash burn, while institutional interest is supported by a recent $13.9M private placement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
